The Online Books Page

Drugs -- Dosage -- Economic aspects -- United States

See also what's at your library, or elsewhere.

• Drugs -- Dosage -- Economic aspects
• Drugs -- United States

• Ensuring kidney patients receive safe and appropriate anemia management care (U.S. G.P.O. :, 2010), by United States. Congress. House. Committee on Ways and Means. Subcommittee on Health (page images at HathiTrust)

Items below (if any) are from related and broader terms.

• Drugs in perspective (National Institute on Drug Abuse, Division of Resource Development, Manpower and Training Branch :, 1979), by National Institute on Drug Abuse. Manpower and Training Branch, Lonnie E. Mitchell, William E. Link, and National Drug Abuse Center (U.S.) (page images at HathiTrust)
• Drugs in travelers' kit. (Center for Disease Control, 1986), by Centers for Disease Control (U.S.) (page images at HathiTrust)
• Guideline for the format and content of the summary for new drug and antibiotic applications. (Center for Drugs and Biologics, Food and Drug Administration, Dept. of Health and Human Services, 1987), by Center for Drugs and Biologics (U.S.) (page images at HathiTrust)
• Guideline on formatting, assembling, and submitting new drug and antibiotic applications. (Center for Drugs and Biologics, Food and Drug Administration, Dept. of Health and Human Services, 1987), by Center for Drugs and Biologics (U.S.) (page images at HathiTrust)
• Guideline for submitting supporting documentation in drug applications for the manufacture of drug substances (U.S. Dept. of Health and Human Services, Public Health Service, Food and Drug Administration, 1987), by Center for Drugs and Biologics (U.S.) (page images at HathiTrust)
• Guideline for submitting documentation for the manufacture of and controls for drug products. (Center for Drugs and Biologics, Food and Drug Administration, Dept. of Health and Human Services, 1987), by Center for Drugs and Biologics (U.S.) (page images at HathiTrust)
• Coverage of prescription drugs under Medicare hearing before the Subcommittee on Health of the Committee on Finance, United States Senate, One Hundredth Congress, first session, June 18, 1987. (U.S. G.P.O., 1988), by United States. Congress. Senate. Committee on Finance. Subcommittee on Health (page images at HathiTrust)
• The Food and Drug Administration's process for approving new drugs : report (U.S. G.P.O. :, 1980), by Research United States. Congress. House. Committee on Science and Technology. Subcommittee on Science (page images at HathiTrust)
• Funding implications of new combination therapies for federal and state programs (The Office, 1998), by United States General Accounting Office and Health and Human Services United States. Congress. Senate. Committee on Appropriations. Subcommittee on Departments of Labor (page images at HathiTrust)
• An FDA consumer memo. (Dept. of Health, Education, and Welfare, Public Health Service, Food and Drug Administration, Office of Public Affairs, 1979), by United States. Food and Drug Administration. Office of Public Affairs (page images at HathiTrust)
• Further investigation of look-alike drugs : hearing before the Select Committee on Narcotics Abuse and Control, House of Representatives, Ninety-seventh Congress, second session, August 12, 1982. (U.S. G.P.O., 1983), by United States. Congress. House. Select Committee on Narcotics Abuse and Control (page images at HathiTrust)
• Federal drug interdiction efforts need strong central oversight : report to the Congress (U.S. General Accounting Office ;, 1983), by United States General Accounting Office (page images at HathiTrust)
• Criminal penalty for robbery of controlled substances : hearing before the Subcommittee on Crime of the Committee on the Judiciary, House of Representatives, Ninety-eighth Congress, first session ... April 7, 1983. (U.S. G.P.O., 1984), by United States. Congress. House. Committee on the Judiciary. Subcommittee on Crime (page images at HathiTrust)
• Spectrophotometric determination of heroine and quinine ... (Govt. Print. Off.], 1955), by United States Internal Revenue Service (page images at HathiTrust)
• Drug regulation reform act of 1978. (U.S. Govt. Print. Off., 1978), by United States Department of Health, Education, and Welfare (page images at HathiTrust)
• Milestones in the war against the narcotic peril / extension of remarks of Walter F. Lineberger of California, in the House of Representatives, Wednesday, February 18, 1925. (G.P.O. ;, 1925), by Water Franklin Lineberger (page images at HathiTrust)
• Uniform narcotic drug act drafted by the National Conference of Commissioners on Uniform State Laws, and by it approved and recommended for enactment in all the states at its forty-second annual conference at Washington, D.C., October 4-10, 1932 ... ([Chicago], 1932), by National Conference of Commissioners on Uniform State Laws (page images at HathiTrust)
• Report on doctor-owned drug enterprises ... (U.S. Govt. Print. Off.?, 1966), by United States House Committee on the Judiciary and United States Food and Drug Administration (page images at HathiTrust)
• Guidelines for the time frame applicable to the review and approval of new drug applications and antibiotic applications. (Datapharm Information Services, Division of Interpharm Press, 1985), by Center for Drugs and Biologics (U.S.) and United States Food and Drug Administration (page images at HathiTrust)
• Guideline for submitting documentation for the stability of human drugs and biologics. (Datapharm Information Services, Division of Interpharm Press, 1987), by Center for Drugs and Biologics (U.S.) and United States Food and Drug Administration (page images at HathiTrust)

• Hair analysis as a drug detector (U.S. Dept. of Justice, Office of Justice Programs, National Institute of Justice, 1995), by Thomas Mieczkowski and National Institute of Justice (U.S.) (page images at HathiTrust)
• Hair assays and urinalysis results for juvenile drug offenders : a summary of research (U.S. Dept. of Justice, Office of Justice Programs, National Institute of Justice, 1997), by Thomas Mieczkowski and National Institute of Justice (U.S.) (page images at HathiTrust)

• HHS SSC Medical supply catalog (The Center, 1996), by Health and Human Services Supply Service Center (U.S.) (page images at HathiTrust)
• Drug list : pharmacy service (Richard L. Roudebush Medical Center, 1984), by United States. Veterans Administration and Richard L. Roudebush Medical Center (U.S.) (page images at HathiTrust)

• Drug registration and listing instruction booklet. (U.S. Dept. of Health and Human Services, Public Health Service, Food and Drug Administration, Center for Drug Evaluation and Research, Product Information Management Branch, 1996), by Center for Drug Evaluation and Research (U.S.). Product Information Management Branch (page images at HathiTrust)

• Final report (U.S. G.P.O. :, 1988), by White House Conference for a Drug Free America (page images at HathiTrust)

• Implications for beneficiaries of Medicare HMO use of formularies (The Office, 1999), by United States General Accounting Office and Medicare+Choice Program (U.S.) (page images at HathiTrust)
• FEHBP plans satisfied with savings and services, but retail pharmacies have concerns (The Office ;, 1997), by United States General Accounting Office (page images at HathiTrust)
• Greater Access to Affordable Pharmaceuticals Act (U.S. G.P.O. :, 2004), by United States Senate Committee on the Judiciary (page images at HathiTrust)
• Medicare reform (U.S. G.P.O. :, 2001), by United States. Congress. House. Committee on Ways and Means. Subcommittee on Health (page images at HathiTrust)

• Medical Technology and Costs of the Medicare Program (OTA-H-227; 1984), by United States Congress Office of Technology Assessment
  • page images at HathiTrust
  • PDF files with commentary at Princeton
  • PDF at unt.edu
• Medicaid : changes in drug prices paid by HMOs and hospitals since enactment of rebate provisions : report to Congressional committees (The Office ;, 1993), by United States General Accounting Office (page images at HathiTrust)
• Medicaid : changes in drug prices paid by VA and DOD since enactment of rebate provisions (The Office, 1991), by United States General Accounting Office (page images at HathiTrust)
• Beneficiary protections in Medicare Part D (U.S. G.P.O. :, 2009), by United States. Congress. House. Committee on Ways and Means. Subcommittee on Health (page images at HathiTrust)
• Prescribed medicines in ambulatory care settings : a comparison of use, expenditures, and sources of payment, 1977 and 1987 (The Agency, 1995), by John F. Moeller, Helen Levy, and Center for General Health Services Intramural Research (U.S.) (page images at HathiTrust)

• Drug regulation : FDA's computer systems need to be better managed : report to the Chairman, Subcommittee on Intergovernmental Relations and Human Resources, Committee on Government Operations, House of Representatives (The Office, 1986), by United States General Accounting Office (page images at HathiTrust)

• Guide to drug abuse research terminology (U.S. Dept. of Health and Human Services, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute on Drug Abuse, 1982), by Jack E. Nelson and National Institute on Drug Abuse (page images at HathiTrust)

• Changes in the oxygen-hemoglobin dissociation curve and time of useful function at hypobaric pressures in rats after chronic oral administration of propranolol (U.S. Dept. of Transportation, Federal Aviation Administration, Office of Aviation Medicine, 1980), by J. M. McKenzie, Civil Aeromedical Institute, and United States. Office of Aviation Medicine (page images at HathiTrust)

• Generic substitution and prescription drug prices : economic effects of state drug product selection laws (Bureau of Economics, Federal Trade Commission, 1985), by Alison Masson, Robert L. Steiner, and United States. Federal Trade Commission. Bureau of Economics (page images at HathiTrust)
• Competitive problems in the pharmaceutical drug industry hearing before the Subcommittee on Antitrust, Monopolies [sic], and Business Rights of the Committee on the Judiciary, United States Senate, One Hundredth Congress, first session, on the generic drug industry and its concerns with respect to competition from the brand name manufacturers, October 21, 1987. (U.S. G.P.O., 1989), by Monopoly United States. Congress. Senate. Committee on the Judiciary. Subcommittee on Antitrust (page images at HathiTrust)
• Implications of drug labeling and off-label use (The Office ;, 1996), by Sarah F. Jagger, United States. Congress. House. Committee on Government Reform and Oversight. Subcommittee on Human Resources and Intergovernmental Relations, and United States General Accounting Office (page images at HathiTrust)
• Generic drug laws : a decade of trial, a prescription for progress (U.S. Dept. of Health and Human Services, Public Health Service, National Center for Health Services Research and Health Care Technology Assessment ;, 1986), by Theodore Goldberg, Ira E Raskin, Carolee A DeVito, and National Center for Health Services Research and Health Care Technology Assessment (U.S.) (page images at HathiTrust)

• Providing for consideration of HR 2427, Pharmaceutical Market Access Act of 2003 (U.S. G.P.O., 2003), by United States House Committee on Rules (page images at HathiTrust)
• Exploring the relationship between doctors and the drug industry (U.S. G.P.O. :, 2008), by United States Senate Special Committee on Aging (page images at HathiTrust)
• Under the influence : can we provide doctors an alternative to biased drug reviews? : hearing before the Special Committee on Aging, United States Senate, One Hundred Tenth Congress, second session, Washington, DC, March 12, 2008. (U.S. G.P.O. :, 2008), by United States Senate Special Committee on Aging (page images at HathiTrust)
• Direct to consumer advertising (U.S. G.P.O. :, 2008), by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations (page images at HathiTrust)
• Prescription Drug Marketing Act of 1987 : hearing before the Subcommittee on International Trade of the Committee on Finance, United States Senate, One Hundredth Congress, first session on S. 368, June 15, 1987. (U.S. G.P.O. :, 1988), by United States. Congress. Senate. Committee on Finance. Subcommittee on International Trade (page images at HathiTrust)
• The Express Scripts/Medco merger : cost savings for consumers or more profits for the middlemen? : hearing before the Subcommittee on Antitrust, Competition Policy and Consumer Rights of the Committee on the Judiciary, United States Senate, One Hundred Twelfth Congress, first session, December 6, 2011. (U.S. G.P.O. :, 2012), by Competition Policy United States. Congress. Senate. Committee on the Judiciary. Subcommittee on Antitrust (page images at HathiTrust)
• FDA user fees 2012 : issues related to accelerated approval, medical gas, antibiotic development, and downstream pharmaceutical supply chain : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Twelfth Congress, second session, March 8, 2012. (Washington : U.S. Government Printing Office, 2013., 2013), by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health (page images at HathiTrust)
• The proposed merger between Express Scripts and Medco : hearing before the Subcommittee on Intellectual Property, Competition, and the Internet of the Committee on the Judiciary, House of Representatives, One Hundred Twelfth Congress, first session, September 20, 2011 (U.S. G.P.O. :, 2011), by Competition United States. Congress. House. Committee on the Judiciary. Subcommittee on Intellectual Property (page images at HathiTrust)

More items available under broader and related terms at left.